BeOne Medicines Ltd. (ONC)
377.37
+5.39
(+1.45%)
USD |
NASDAQ |
Aug 25, 11:13
BeOne Medicines EPS Diluted (Quarterly) : 2.050 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.050 |
| March 31, 2026 | 1.970 |
| December 31, 2025 | 0.5789 |
| September 30, 2025 | 1.092 |
| June 30, 2025 | 0.841 |
| March 31, 2025 | 0.0114 |
| December 31, 2024 | -1.424 |
| September 30, 2024 | -1.146 |
| June 30, 2024 | -1.15 |
| March 31, 2024 | -2.409 |
| December 31, 2023 | -3.532 |
| September 30, 2023 | 2.014 |
| June 30, 2023 | -3.643 |
| March 31, 2023 | -3.345 |
| December 31, 2022 | -4.292 |
| September 30, 2022 | -5.388 |
| June 30, 2022 | -5.469 |
| March 31, 2022 | -4.253 |
| December 31, 2021 | -6.228 |
| September 30, 2021 | -4.729 |
| June 30, 2021 | -5.230 |
| March 31, 2021 | 0.6874 |
| Date | Value |
|---|---|
| December 31, 2020 | -5.161 |
| September 30, 2020 | -4.811 |
| June 30, 2020 | -4.314 |
| March 31, 2020 | -4.703 |
| December 31, 2019 | -6.295 |
| September 30, 2019 | -5.113 |
| June 30, 2019 | -1.431 |
| March 31, 2019 | -2.813 |
| December 31, 2018 | -4.492 |
| September 30, 2018 | -2.412 |
| June 30, 2018 | -2.627 |
| March 31, 2018 | -1.752 |
| December 31, 2017 | -1.663 |
| September 30, 2017 | 1.966 |
| June 30, 2017 | -1.014 |
| March 31, 2017 | -0.8477 |
| December 31, 2016 | -0.6296 |
| September 30, 2016 | -0.5944 |
| June 30, 2016 | -0.404 |
| March 31, 2016 | -0.3684 |
| December 31, 2015 | -0.4594 |
| September 30, 2015 | -0.5034 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| CRISPR Therapeutics AG | -0.9445 |
| Basilea Pharmaceutica AG | -- |
| Santhera Pharmaceuticals Holding AG | -- |
| AC Immune SA | 0.026 |
| Idorsia Ltd. | -0.5293 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 237.40M |
| Revenue (Quarterly) | 1.708B |
| Total Expenses (Quarterly) | 1.470B |
| Enterprise Value | 35.54B |
| Gross Profit Margin (Quarterly) | 87.80% |
| Profit Margin (Quarterly) | 13.90% |
| Earnings Yield | 1.51% |
| Operating Earnings Yield | 2.13% |
| Normalized Earnings Yield | 1.587 |